JAMEELA MITCHELL: Open Payments
NPI 1275044224 · BALTIMORE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,758 in 73 payments from 10 companies in 2025. Trend: 2023 $1,261 · 2024 $869 · 2025 $1,758
Food & beverage: $1,758
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 22 | $521 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $340 |
| Indivior Inc. | 8 | $212 |
| Braeburn Inc. | 7 | $198 |
| Neurocrine BioSciences, Inc. | 7 | $165 |
| Alkermes, Inc. | 5 | $112 |
| Lundbeck LLC | 4 | $77 |
| Otsuka America Pharmaceutical, Inc. | 3 | $63 |
| Orexo US, Inc. | 3 | $54 |
| Axsome Therapeutics, Inc. | 1 | $17 |
Products named: VRAYLAR, CAPLYTA, SUBLOCADE, BRIXADI, INGREZZA, VIVITROL, ABILIFY MAINTENA, ABILIFY ASIMTUFII.
Industry payments across MD — which companies pay providers there.
